Sno	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	18/LO/0068	235852	Phase 1, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)	Number Agreed	1	1	Date Agreed	31/10/2019	0	10/10/2018	0	Withdrawn By Sponsor
2	18/NE/0200	244356	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX 445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)	Range Agreed	1	3	Date Agreed	31/10/2018	3	31/10/2018	3	Recruitment Finished
3	15/NW/0769	171345	CTP005 - A Feasibility study of the Use of ReCell? Autologous Cell Harvesting Device for Diabetic Foot Ulcers	Range Agreed	6	21	Date Agreed	31/12/2018	11	31/12/2018	11	Recruitment Finished
4	15/NE/0167	171524	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation	Number Agreed	2	2	Date Agreed	31/10/2018	2	08/10/2018	2	Recruitment Finished
5	17/YH/0313	232939	RelAxCough	Range Agreed	10	15	Date Agreed	30/11/2018	12	29/12/2018	12	Recruitment Finished
6	17/EM/0324	225749	A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotidecapsules in patients who previously tolerated and demonstrated biochemical control on injectable somatostatinreceptor ligands (SRL	Range Agreed	1	2	Date Agreed	31/08/2018	2	01/10/2018	2	Recruitment Finished
7	16/EM/0193	190690	A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib oncardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): Thedal-GenE trial?.	Number Agreed	6	6	Date Agreed	01/11/2018	13	01/11/2018	13	Recruitment Finished
8	15/NW/0142	164099	Adapt Response	Number Agreed	20	20	Date Agreed	31/01/2019	10	31/01/2019	10	Recruitment Finished
9	15/WM/0453	172946	An Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 versus Fulvestrant in Postmenopausal Women with ER positive HER-2 negative Primary Breast Cancer	Number Agreed	1	1	Date Agreed	31/12/2018	6	11/01/2019	6	Recruitment Finished
10	18/LO/0782	245936	A Randomized, Double Masked, Uncontrolled, Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Na?ve Participants with Neovascular Age-Related Macular Degeneration (AMD)	Range Agreed	1	4	Date Agreed	01/03/2019	1	01/03/2019	1	Recruitment Finished
11	18/EM/0228	248988	A double blind, placebo-controlled study to assess the anti-viral effect, safety and tolerability of inhaled PC786 for the treatment of acute respiratory syncytial virus (RSV) infection in adult hematopoietic stem cell transplant recipients	Number Agreed	3	3	Date Agreed	11/03/2019	1	12/03/2019	1	Recruitment Finished

Sno	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
12	16/LO/1012	205250	A Phase 3b, Two-part, Multicenter, One Year Randomized, Double-blind,Placebo-controlled Trial of the Safety, Pharmacokinetics, Tolerability, and Efficacy ofTolvaptan followed by a Two Year Open-label Extension in Children and AdolescentSubjects with	Range Agreed	1	5	Date Agreed	18/10/2020	9	15/11/2018	9	Recruitment Finished
13	16/NE/0255	200900	External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment with Raxone? in Leber?s Hereditary Optic Neuropathy (LHON)	Range Agreed	1	3	Date Agreed	08/03/2019	7	08/03/2019	7	Recruitment Finished
14	17/LO/0113	219400	A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally toPatients With Sickle Cell Disease	Range Agreed	1	6	Date Agreed	30/06/2018	2	19/03/2019	2	Recruitment Finished
15	17/SC/0237	220963	A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety,tolerability, pharmacodynamics, and pharmacokinetics of different doses of orally administered BI 1467335 during a12-week treatment pe	Number Agreed	4	4	Date Agreed	18/12/2018	1	07/02/2019	1	Recruitment Finished
16	16/LO/0878	201070	Prospective, multi-centre study to evaluate the everlinQ endoAVF System when used to create an endovascular arteriovenous fistula (endoAVF) for patients who require vascular access for haemodialysis.	Range Agreed	15	20	Date Agreed	31/12/2019	13	06/03/2019	13	Recruitment Finished
17	15/EM/0543	176792	A Randomized, Open-label, Controlled Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With High-risk Fi	Range Agreed	1	5	Date Agreed	30/11/2018	1	11/03/2019	1	Withdrawn By Host
18	15/YH/0478	186697	A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	Range Agreed	1	4	Date Agreed	30/06/2019	4	17/06/2019	4	Recruitment Finished
19	16/SC/0615	210762	A Phase 4 open-label randomized controlled study COmparing the effectiveness of adalimumab iNTROduction andmethotrexate dose escaLation in subjects with Psoriatic Arthritis (CONTROL)	Range Agreed	1	5	Date Agreed	15/10/2018	11	07/05/2019	12	Recruitment Finished
20	16/WM/0436	208631	A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma	Range Agreed	1	3	Date Agreed	05/02/2019	0	03/01/2019	0	Recruitment Finished
21	16/WM/0511	218115	A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF with or without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elec	Number Agreed	1	1	Date Agreed	31/12/2019	0	23/04/2019	0	Recruitment Finished
22	17/EE/0474	229785	An Open-Label, Randomized, Multi-Center, Parallel Group, Two-Arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir versus Standard of Care for Treatment of Adenovirus Infections in High-Risk Pediatric Allogenei	Range Agreed	1	4	Date Agreed	31/05/2019	3	09/05/2019	3	Withdrawn By Sponsor

Sno	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
23	17/EM/0063	213979	A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remi	Range Agreed	1	3	Date Agreed	31/03/2019	0	10/04/2019	0	Withdrawn By Sponsor
24	17/EM/0404	223875	A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjuncti	Range Agreed	1	10	Date Agreed	31/12/2020	2	03/05/2019	2	Withdrawn By Sponsor
25	17/LO/0041	219676	CardioMEMS Heart Failure System "Outside US" Post-Approval Study	Range Agreed	1	10	Date Agreed	01/09/2019	7	21/06/2019	7	Recruitment Finished
26	17/LO/0372	220433	A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation	Range Agreed	1	3	Date Agreed	07/05/2019	3	07/05/2019	3	Recruitment Finished
27	17/LO/1930	235819	A randomized, controlled, open-label, multiple ascending dose study of intravenous brincidofovir in adult allogeneic hematopoietic cell transplant recipients with adenovirus viremia	Range Agreed	1	2	Date Agreed	30/09/2019	0	09/05/2019	0	Withdrawn By Sponsor
28	17/NE/0124	216591	A randomised, double-blind, controlled, parallel-group, multi-country study to investigate the effect of a partially hydrolysed infant formula with added synbiotics on gut microbiota composition and clinical effectiveness in infants at high risk of d	Range Agreed	1	3	Date Agreed	28/02/2019	1	28/02/2019	1	Recruitment Finished
29	17/NI/0096	225743	HOPE-1 (HYDRATION FOR OPTIMAL PULMONARY EFFECTIVENESS)	Range Agreed	2	4	Date Agreed	10/11/2018	2	01/04/2019	3	Withdrawn By Host
30	17/NW/0209	213231	An open-label ascending dose cohort study to assess the safety, pharmacokinetics, and preliminary efficacy ofneoGAA (GZ402666) in patients with infantile-onset Pompe disease treated with alglucosidase alfa who demonstrateclinical decline or sub-optim	Range Agreed	1	3	Date Agreed	19/04/2019	1	19/04/2019	1	Recruitment Finished
31	17/SC/0462	228889	A Randomized, Double-blind Phase 1/2a Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.preF in Adults 18 to 50 Years of Age and RSV-Seropositive Toddlers 12 to 24 Months of Age	Number Agreed	4	4	Date Agreed	31/03/2018	0	14/06/2019	4	Recruitment Finished
32	17/SW/0221	232448	A randomized, partially-blinded, active-controlled,multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy	Number Agreed	4	4	Date Agreed	03/11/2021	0	16/05/2019	0	Withdrawn By Sponsor
33	18/NE/0221	249183	A Phase I, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects with Mucopolysaccharidosis II (MPSII)	Range Agreed	1	4	Date Agreed	31/08/2019	0	25/04/2019	0	Withdrawn By Sponsor

Sno	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
34	18/SW/0162	248769	A prospective follow up study to assess performance, safety and efficacy of the PICO 7 NPWT system for surgically closed incision sites and skin grafts	Range Agreed	5	8	Date Agreed	29/03/2019	9	21/05/2019	9	Recruitment Finished
35	15/NE/0278	183395	An open-label, randomized, active-controlled,parallel-group, Phase-3b study of theefficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injectionsusing two different treatment regimens to subjects withneovascular age-rela	Number Agreed	5	5	Date Agreed	30/04/2019	9	28/02/2019	9	Recruitment Finished
36	14/LO/0122	141557	A multicentre, openlabel, nonrandomised, phase I dose escalation study of regorafenib (BAY 734506) in paediatric subjects with solid malignant tumours that are recurrent or refractory to standard therapy.	Number Agreed	2	2	Date Agreed	31/03/2019	3	31/03/2019	3	Recruitment Finished
37	16/LO/0718	203652	A phase 3, multicentre, single-arm, open-label study of the efficacy and safety of B-domain deleted recombinant porcine factor VII (BAX802) in subjects with congenital haemophilia A with factor VIII inhibitors undergoing surgical or other invasive pr	Range Agreed	1	2	Date Agreed	01/07/2020	0	22/05/2019	0	Withdrawn By Host
38	16/LO/1602	210033	An open-label adaptive study for the assessment of safety, tolerability, pharmacokinetics, and the efficacy of multiple doses of Radiprodil in subjects with drug-resistant infantile spasms.	Range Agreed	1	3	Date Agreed	01/06/2018	0	02/10/2018	0	Withdrawn By Sponsor
39	17/LO/1103	230709	Two-part, double-blind, placebo-controlled, randomized, parallel-group study: (Part 1) in healthy male volunteers to assess safety and tolerability of ascending repeated oral doses of BAY 1817080, followed by (Part 2), two-way crossover administratio	Number Agreed	6	6	Date Agreed	26/11/2018	5	06/03/2019	6	Recruitment Finished
40	17/NE/0200	220486	Strategic MAnagement to Optimize Response To CardiacResynchronization Therapy Registry (SMART Registry)	Number Agreed	12	12	Date Agreed	31/08/2019	27	19/08/2019	27	Recruitment Finished
41	17/NE/0358	220871	Relative bioavailability and comparative pharmacokinetics of 13-CRA oral liquid and extracted capsule formulations: a randomised, open label, multi-dose, cross-over clinical trial in patients requiring treatment cycles of 13-CRA.	Range Agreed	2	3	Date Agreed	30/11/2019	2	17/07/2019	2	Recruitment Finished
42	17/NW/0247	222303	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy	Number Agreed	5	5	Date Agreed	31/03/2025	1	30/09/2019	1	Recruitment Finished
43	17/NW/0399	224760	Study of the measurement of volatile agents to diagnose urological disease	Range Agreed	90	150	Date Agreed	31/07/2019	82	31/08/2019	82	Recruitment Finished
44	17/WA/0347	234208	A randomised, double-blind, placebo-controlled, parallel-group, multicentre study to demonstrate the effects ofSotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors andModerately Impaired Renal	Number Agreed	12	12	Date Agreed	31/12/2019	14	16/09/2019	14	Recruitment Finished

Sno	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
45	17/YH/0426	231118	A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly with Topical Corticosteroids in Patients, =6 Years to <12 Years Of Age, with Severe Atopic Dermatitis	Range Agreed	2	20	Date Agreed	30/09/2018	5	21/08/2019	5	Recruitment Finished
46	17/YH/0432	236091	A double blind (sponsor open) placebo-controlled, stratified, parallelgroup study to evaluate the efficacy and safety of repeat doses of GSK3772847 inparticipants with moderate to severe asthma with allergic fungal airway disease (AFAD).	Range Agreed	3	5	Date Agreed	28/06/2019	0	30/06/2019	0	Withdrawn By Sponsor
47	18/EE/0005	232671	A Multicenter, Open-Label Study To Estimate The Effect Sizes Of HRCT Endpoints In Response To Glucocorticoid Induction Therapy In Subject With Pulmonary Sarcoidsis	Number Agreed	2	2	Date Agreed	31/08/2019	0	04/09/2019	0	Withdrawn By Sponsor
48	18/LO/0190	227705	Clinical investigation of the eyeWatch glaucoma drainage device	Number Agreed	15	15	Date Agreed	31/05/2019	15	31/05/2019	15	Recruitment Finished
49	18/LO/0656	240062	Multiple escalating dose study of BAY 1093884 in adults with Haemophilia A or B with or without inhibitors	Number Agreed	1	1	Date Agreed	16/07/2020	1	05/08/2019	1	Withdrawn By Sponsor
50	18/LO/0711	241788	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN030)	Number Agreed	8	8	Date Agreed	07/08/2019	5	12/08/2019	5	Recruitment Finished
51	18/LO/0712	241782	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN027)	Number Agreed	8	8	Date Agreed	07/08/2019	8	17/05/2019	8	Recruitment Finished
52	18/LO/1007	242697	Patient-Reported Outcomes with the Accu-Chek? SoloMicropump System vs. Insulet OmniPod? vs. Multiple DailyInjection Therapy in Type 1 Diabetes	Range Agreed	1	4	Date Agreed	31/07/2019	4	31/07/2019	4	Recruitment Finished
53	18/LO/1311	248599	A phase III, multicenter, randomized, double-masked, active comparatorcontrolled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema (RHINE)	Number Agreed	2	2	Date Agreed	31/12/2019	2	22/08/2019	2	Recruitment Finished
54	18/NE/0102	240702	A phase I, open?label, randomized, pharmacokinetic, pharmacodynamic, and safety study ofEtrolizumab followed by open?label extension and safety monitoring in paediatric patientsFrom 4 years to less than 18 years of age with moderate to severe ulcerat	Number Agreed	1	1	Date Agreed	31/12/2019	2	20/08/2019	2	Recruitment Finished
55	18/NE/0266	241641	A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation	Range Agreed	2	3	Date Agreed	31/01/2019	4	20/02/2019	4	Recruitment Finished

Sno	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
56	18/NW/0098	242717	Two-part, double-blind, placebo-controlled, randomized, parallel-group study: (Part 1) in healthy male subjects to assess safety and tolerability of ascending repeated oral doses of BAY 1902607 including its effect on the pharmacokinetics of a sub-th	Number Agreed	2	2	Date Agreed	30/04/2019	2	05/07/2019	3	Recruitment Finished
57	18/NW/0742	236247	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple Osteochondromas	Range Agreed	4	15	Date Agreed	30/06/2019	3	09/08/2019	6	Withdrawn By Host
58	18/WM/0204	244427	A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation	Range Agreed	1	3	Date Agreed	31/08/2019	3	18/04/2019	3	Recruitment Finished
59	19/EM/0003	251874	A Randomized, Double-Blind, Placebo Controlled, Global Phase 3 Study Of Edasalonexent In Pediatric Patients With Duchenne Muscular Dystrophy	Range Agreed	1	3	Date Agreed	30/09/2019	5	30/09/2019	5	Recruitment Finished
60	19/NW/0026	249432	VX18-121-101: A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older with Cystic Fibrosis	Range Agreed	1	4	Date Agreed	30/09/2019	6	30/08/2019	6	Recruitment Finished
61	18/EM/0365	252018	An open-label extension trial of the long-term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD	Number Agreed	3	3	Date Agreed	31/07/2019	3	31/07/2019	3	Recruitment Finished